Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Paraganglioma

Paraganglioma

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Paraganglioma

7 trials tracked for Paraganglioma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 182 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 6
  1. Phase 3 Preoperative Alpha Blockade for Pheochromocytoma Completed · 182 cited
  2. Phase 2 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed
  3. Phase 2 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Completed
  4. Phase 2 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Completed
  5. Phase 2 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed
  6. Phase 2 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed
Show 1 more trials
  1. Phase 2 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Paraganglioma: what the trials found

Clinical evidence regarding the management of hemodynamic instability in patients with paraganglioma indicates that phenoxybenzamine was evaluated for this purpose. In a Phase 3 study, there was no statistically significant difference in the incidence of hemodynamic instability between the treatment groups (14 vs. 13; p=.56) 1.

Recent results — preliminary, needs further review

  • Cabozantinib (40 mg) was evaluated in a Phase 2 trial for paraganglioma, but results are not yet corroborated 2.
  • Sunitinib demonstrated a Clinical Benefit Rate (CBR), defined as PR, CR, or SD for ≥ 12 weeks, of 19 out of 25 patients 3.
  • Linsitinib showed a Clinical Benefit Rate (defined as SD ≥ 9 months, PR, or CR) in 40 out of 50 patients 6.
  • Axitinib (AG-013736) was evaluated in a Phase 2 trial 4.
  • Two separate trials investigated the use of MIBG isotopes (131I-MIBG and Ultratrace Iobenguane MIBG I 131) for this condition [5, 7].

For the clinician treating this condition

  • Phenoxybenzamine did not show a statistically significant difference in reducing hemodynamic instability compared to the control group in Phase 3 trials 1.
  • Multiple targeted therapies and radiopharmaceuticals (including Sunitinib, Linsitinib, Cabozantinib, Axitinib, and MIBG isotopes) are currently under investigation or have shown preliminary clinical benefit rates, but these findings are not yet corroborated as established standard evidence [2, 3, 4, 5, 6, 7].

AI synthesis of 5 cited trials, updated Jul 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MITF E318K variant associated with significantly increased melanoma risk and high nevus burden
Oncology Meta-analysis
MITF E318K variant associated with significantly increased melanoma risk and high nevus burden Specific gene variant linked to higher risk of multiple melanomas
This systematic review and meta-analysis of 8,606 melanoma patients and 17,953 controls identifies the MITF E318K variant as a moderate-pene…
A specific genetic variant called MITF E318K is linked to a significantly higher risk of developing multiple primary melanomas.
Sep 20, 2026
Necrotic alterations in paragangliomas are associated with higher metastasis rates and cardiovascular complications
Oncology Meta-analysis
Necrotic alterations in paragangliomas are associated with higher metastasis rates and cardiovascular complications Necrotic Alterations Linked to Higher Metastasis in Paragangliomas
This meta-analysis and retrospective study evaluate the clinical implications of necrotic versus cystic alterations in patients with confirm…
Research shows that tumors with necrotic tissue are linked to higher metastasis rates and more cardiovascular complications in patients with…
Aug 23, 2026
Radiomics and deep learning provide promising tools for precise assessment of adrenal masses
Diabetes & Endocrinology Sys. Review
Radiomics and deep learning provide promising tools for precise assessment of adrenal masses AI and radiomics show promise for adrenal tumor diagnosis
This systematic review evaluates the utility of radiomics and deep learning (DL) techniques in assessing adrenal masses including pheochromo…
A new review finds AI-powered imaging analysis could improve how doctors diagnose adrenal masses, but clinical use is still far off.
Frontiers Jul 30, 2026
No established correlation exists between paragangliomas and cervical lymph node metastasis in papillary thyroid carcinoma
Oncology Sys. Review
No established correlation exists between paragangliomas and cervical lymph node metastasis in papillary thyroid carcinoma Distinguishing Between Thyroid Cancer and Paraganglioma for Better Diagnosis
This case report and literature review examines the relationship between paragangliomas and cervical lymph node metastasis in patients with …
Doctors must accurately distinguish between thyroid cancer and paragangliomas to ensure correct treatment plans and accurate patient prognos…
Frontiers Jul 30, 2026
SDHD Variant Carriers Face High Penetrance and Multifocal Tumors
Oncology Meta-analysis
SDHD Variant Carriers Face High Penetrance and Multifocal Tumors SDHD Genetic Variants Linked to Increasing Risk of Tumors Over Time
A meta-analysis of SDHD pathogenic variant carriers reveals age-specific penetrance rising to 82% by age 60, with 75% developing multifocal …
New data shows that the risk of developing tumors increases significantly with age for people carrying specific SDHD genetic variants.
Jul 26, 2026

Questions about Paraganglioma

What is the risk of metastasis for patients with the SDHD mutation and paraganglioma?

For people with an SDHD mutation who develop paraganglioma, the risk of metastasis appears to be low, around 4% in one meta-analysis, much lower than for SDHB mutations [6].

Full answer →
Do SDHD gene mutations cause multiple paraganglioma tumors?

Yes. SDHD mutations are a major cause of hereditary paragangliomas, and carriers often develop multiple tumors, with penetrance rising with age [5][6][7].

Full answer →
Are there links between paraganglioma and thyroid cancer lymph node spread?

Some inherited gene mutations can raise the risk of both paraganglioma and thyroid cancer, but the sources do not show that paraganglioma directly causes thyroid cancer lymph node spread.

Full answer →